ESMO Welcomes the Adoption of the 2017 WHO Cancer Resolution

Food and Healthcare Press Releases Friday June 2, 2017 09:02
LUGANO, Switzerland--2 Jun--PRNewswire/InfoQuest

ESMO, the leading European professional organisation for medical oncology, welcomes the adoption of the Resolution on Cancer prevention and control in the context of an integrated approach [ ]   during the 70th World Health Assembly (WHA), 22-31 May, Geneva, Switzerland.

ESMO President Fortunato Ciardiello said "ESMO welcomes the WHO resolution that aims to ensure access to safe, effective and affordable care for cancer patients. Sustainability of cancer care is one of the three pillars of the ESMO 2020 Vision. As medical oncologists treating cancer patients, we strongly advocate for equal access to quality treatment. Our support to the stakeholders involved in this landmark WHO Resolution is a clear sign of ESMO's pledge towards a world where cancer patients are taken care of by highly specialised professionals."

"The last WHO Cancer Resolution dates back to 2005 []. ESMO has been working with the WHO for many years to improve cancer care," Ciardiello added. "It is crucial that with the number of new cancer cases rising, and over 14 million new cases being diagnosed worldwide every year [], there is a global and joint effort not only to prevent cancer, but also to ensure that those affected by the disease get optimal treatment and care, wherever they live, whatever their economic conditions are."

The 2017 WHO Cancer Resolution calls for national cancer control plans, high quality cancer registries, increased cancer research, use of clinical practice guidelines, timely access to medicines, medical devices and palliative care, as well as a well-trained oncology workforce. "ESMO is active in all these areas and committed to providing quality information, resources and the best education for cancer professionals," stated Ciardiello.

Full story:
ESMO Press Office
Source: European Society for Medical Oncology (ESMO)

Latest Press Release

Semaglutide Injection Phase 2 Data Presented at ENDO Demonstrated Significant Weight Loss in Adults With Obesity

Adults with obesity treated with semaglutide 0.4 mg administered once-daily via subcutaneous injections lost up to 13.8% of their body weight after 52 weeks in a phase 2 trial, significantly more than those treated with placebo who lost 2.3% of their...

FDI Global Survey Shows Children are not Getting Dental Check-ups Early Enough

On the occasion of World Oral Health Day, FDI World Dental Federation asked parents around the world how they cared for their children's oral health growing up and the responses suggest room for improvement. Maintaining a healthy mouth is crucial to...

Texas Cardiac Arrhythmia Institute at St. David#s Medical Center draws cardiac experts from across the globe for EPLive 2018

On March 1 and 2, 2018, the Texas Cardiac Arrhythmia Institute (TCAI) at St. David's Medical Center hosted its fourth international symposium on complex arrhythmias, EPLive 2018. Nearly 200 leaders in the field of electrophysiology (EP) from Europe, Asia...

Johnson Johnson Announces Binding Offer from Platinum Equity to Acquire LifeScan, Inc.

Johnson & Johnson (NYSE: JNJ) today announced that it has received a binding offer from Platinum Equity, a leading private investment firm, to acquire its LifeScan business for approximately $2.1 billion, subject to customary adjustments. LifeScan,...

Biotherm Hosts the First Biotherm Healing Summit

Biotherm hosted the first "Biotherm Healing Summit" on March 7. A symposium on the theme of skin & healing, focusing on major research that has evidenced the link between micro-organisms and skin health. Unveiling Life PlanktonTM, the healing...

Related Topics